Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient

Kim, Jean Hee; Park, Silvia; Kim, Woojun

doi:10.1007/s10072-022-06124-6

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixteen case reports ( 21 , 24 , 27 , 31 , 33 , 35 , 40 – 45 , 64 , 67 , 69 , 74 ) and two case series ( 48 , 77 ) described the occurrence of hematological disorders after alemtuzumab treatment. Of these studies, 5 concerned the occurrence of early-onset toxicities ( 40 , 42 , 43 , 48 , 67 ), including severe cases of leukopenia, neutropenia, lymphopenia and thrombocytopenia that occurred in four female and one male patients, aged <58 years, with a medication history that included at least IFN and/or natalizumab for all of them.…”

Section: Resultsmentioning

confidence: 99%

“…Apart from one case that resulted in patient’s death ( 43 ), the remaining ones described the occurrence of hematological toxicities resulted in a full recovery. Alemtuzumab-induced late-onset hematological disorders were instead described in the remaining case reports and series ( 24 , 27 , 31 , 33 , 35 , 41 , 44 , 45 , 64 , 69 , 77 ). These events occurred in 8 male and 4 female patients [in one case ( 35 ) the sex was not reported].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series

Scavone,

Liguori,

Adungba

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

IntroductionDisease modifying therapies (DMTs) used to treat multiple sclerosis (MS) can be associated to the occurrence of hematological disorders. This systematic review aims to provide an overview of these events occurring in real-life conditions, by describing case reports and series published in the literature.MethodsA literature search of all publications up to January 5th 2024 on the Medline and Embase databases was carried out. The results were presented both in the text and in tables.ResultsSixty-seven case reports/series were included in this review, of which more than half related to alemtuzumab, natalizumab and ocrelizumab. The publication date of included studies ranged from 2006 to 2024. The majority of case reports and series described the occurrence of late-onset hematological disorders (events that occurred more than 30 days after the first DMT administration), mainly represented by case of neutropenia, autoimmune hemolytic anemia and immune thrombocytopenia. All cases reported a favorable outcome, apart one case report that described a fatal case. Among included cases, 4 articles, all related to natalizumab, described the occurrence of myeloid disorders in 13 newborns from mother receiving the DMT.DiscussionConsidering the limitations identified in the majority of included studies, further ad hoc studies are strongly needed to better evaluate the hematological disorders of DMTs. Meantime, the strict monitoring of treated patients for the occurrence of these toxicities should be highly recommended.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series

Scavone,

Liguori,

Adungba

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Apart from one case that resulted in patient's death (43), the remaining ones described the occurrence of hematological toxicities resulted in a full recovery. Alemtuzumabinduced late-onset hematological disorders were instead described in the remaining case reports and series (24,27,31,33,35,41,44,45,64,69,77). These events occurred in 8 male and 4 female patients [in one case (35) the sex was not reported].…”

Section: Alemtuzumab-induced Hematological Disordersmentioning

confidence: 99%